RADIOTHERAPY VERSUS RADIOTHERAPY ENHANCED BY CISPLATIN IN STAGE-III NON-SMALL-CELL LUNG-CANCER
RADIOTHERAPY VERSUS RADIOTHERAPY ENHANCED BY CISPLATIN IN STAGE-III NON-SMALL-CELL LUNG-CANCER
复制标题
DOI：
10.1016/0360-3016(92)91014-e
复制
发表时间：
1992-01-01
影响因子：
7
通讯作者：
MONFARDINI, S
中科院分区：
文献类型：
--
作者：
TROVO, MG;MINATEL, E;MONFARDINI, S
从1987年1月至1991年6月，173例不能手术的III期非小细胞肺癌患者进入一项随机试验，比较单纯放疗(45 Gy15次/3周)(A组)和放疗加小剂量顺铂(6 mg/m2)(B组)的疗效。A组总有效率为58.9%，B组为50.6%。两个治疗组之间在复发模式上没有发现差异。中位进展时间A组为10.6个月，B组为14.2个月，中位生存期分别为10.3个月和9.97个月。毒性可以接受，两个治疗方案中都没有发生与治疗相关的死亡。在这项研究中，没有发现联合治疗比单纯放射治疗有明显的优势。在一些试验中取得的令人鼓舞的结果以及该病的难治性表明，应进一步努力优化临床试验方案，也许可以通过审查联合治疗的放射生物学和药理学基础来实现。
Between January 1987 and June 1991, 173 patients with inoperable non-small cell lung cancer, Stage III, were entered into a randomized trial comparing radiotherapy only (RT) (45 Gy/15 fractions/3 weeks) (arm A) versus RT and a daily low dose of cDDP (6 mg/m2) (arm B). An overall response rate of 58.9% was observed in arm A and 50.6% in arm B, respectively. No differences in the pattern of relapse were noted between the two treatment groups. Median time to progression was 10.6 months for arm A and 14.2 months for arm B. Median survivals were 10.3 months and 9.97 months, respectively. Toxicity was acceptable and no treatment-related death occurred in either treatment schedule. In this study no significant advantage of the combined treatment over radiation therapy only was found. The encouraging results achieved in some trials together with the intractability of the disease suggest that further efforts should be made to optimize clinical trial protocols, perhaps by reviewing the radiobiological and pharmacological basis of the combined treatment.